Participant benefits throught hypertension clinical trials
نویسندگان
چکیده
منابع مشابه
Clinical Trials for Hypertension
Current projections predict that, by the year 2025, 29.2% of the adult population worldwide will have hypertension, a total of 1.56 billion people.1 Such figures are hard to visualize, as are the billions of dollars being spent on the Iraqi invasion. Enough to say that hypertension is now and has long been the most common risk for the most common causes of death in all but the most primitive po...
متن کاملMajor Clinical Trials of Hypertension
The National Heart, Lung, and Blood Institute assembled an ad hoc working group to evaluate opportunities for new major clinical trials in the field of hypertension. The mandate of this working group was to consider the possible designs of major randomized clinical trials focused on clinical outcomes that might merit significant investment by the National Institutes of Health. The group conclud...
متن کاملPatient Disposition 1 REPORTING ON PARTICIPANT DISPOSITION IN CLINICAL TRIALS
Preparation of this manuscript was supported in part by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR/AI44724, AR47298), the National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research (HD33989), and the Fetzer Institute. Portions of this paper were summarized at the second meeting of the Initiative on ...
متن کاملEvaluation of Clinical Trials
In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...
متن کاملFuture of clinical trials for pulmonary hypertension.
In 1995, the first successful randomized controlled trial (RCT) for pulmonary arterial hypertension (PAH) led to the approval of the pulmonary vasodilator epoprostenol.1 Under the assumption that PAH was a disease of inappropriate pulmonary vasoconstriction, testing a drug that had vasodilator properties seemed reasonable. The 6-minute walk test was the primary end point in the trial because it...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hypertension
سال: 2004
ISSN: 0895-7061
DOI: 10.1016/j.amjhyper.2004.03.495